A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03372057|
Recruitment Status : Active, not recruiting
First Posted : December 13, 2017
Last Update Posted : February 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Peripheral T-cell Lymphoma||Drug: Duvelisib||Phase 2|
The study has 2 phases, a Dose Optimization Phase and an Expansion Phase.
In the Dose Optimization Phase, patients will be randomly assigned to 1 of 2 study cohorts, as follows:
- Cohort 1: Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
- Cohort 2: Duvelisib 75 mg PO BID, administered in 28-day cycles .
A total of 20 patients will be enrolled in the Dose Optimization Phase, with 10 patients per cohort. Based on the safety and activity data obtained in the Dose Optimization Phase of the study, the Expansion Phase dose of Duvelisib will be determined.
In the Expansion Phase, approximately 90-100 patients may be enrolled and will receive Duvelisib dose in 28-day cycles as determined in Dose Optimization Phase.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)|
|Actual Study Start Date :||February 22, 2018|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||September 2023|
Experimental: Dose Optimization Phase: Cohort 1
Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
Experimental: Dose Optimization Phase: Cohort 2
Duvelisib 75 mg PO BID, administered in 28-day cycles.
Duvelisib PO 75 mg BID in 28-day cycles.
Experimental: Expansion Phase
Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)
Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
- Objective response rate (ORR) [ Time Frame: From start of treatment to first documented response, assessed up to 2 cycles (58 days) ]Best response of CR or PR
- Overall response rate (ORR) [ Time Frame: From start of treatment until disease progression or unacceptable toxicity, assessed up to 2 cycles (58 days) ]
- Number of participants with Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v4.0 [ Time Frame: From start of treatment to end of treatment plus 30 days; 7 months ]
- Duration of Response (DOR) [ Time Frame: Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months ]
- Progression-free survival (PFS) [ Time Frame: Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months ]
- Disease control rate (DCR) [ Time Frame: Greater than or equal to 8 weeks ]
- Overall survival (OS) [ Time Frame: From start of treatment until death, 6 months ]
- Percentage of patients who receive the optimal dose of duvelisib [ Time Frame: From start of treatment to end of cycle 1 (each cycle is 28 days) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age ≥ 18 years of age
Diagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization:
- Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS);
- Angioimmunoblastic T-cell lymphomas (AITL);
- Anaplastic large cell lymphoma (ALCL); or
- Natural-killer/T-cell lymphoma (NKTL)
Received at least 2 cycles of one prior regimen administered with curative intent and one of the following:
- failed to achieve at least a partial response after 2 or more cycles;
- failed to achieve a complete response after 6 or more cycles; and/or
- progressed after an initial response
- For patients with CD30+ ALCL, failed or are ineligible or intolerant to brentuximab vedotin
- Measurable disease as defined by IWG for PTCL, i.e., at least 1 measurable disease lesion > 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CT
- Clinical evidence of transformation to a more aggressive subtype of lymphoma
- Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor
- Known central nervous system involvement by PTCL
- Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids > 20 mg of prednisone (or equivalent) once daily (QD)
- Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03372057
|Other Study ID Numbers:||
|First Posted:||December 13, 2017 Key Record Dates|
|Last Update Posted:||February 21, 2023|
|Last Verified:||February 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Immune System Diseases